Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NovoCure Limited
  6. Summary
    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
91.37(c) 82.06(c) 83.3(c) 89.94(c) 92.74(c) Last
497 240 994 826 761 323 699 811 641 342 Volume
+0.33% -10.19% +1.51% +7.97% +3.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 534 M - -
Net income 2021 -40,2 M - -
Net Debt 2021 215 M - -
P/E ratio 2021 -230x
Yield 2021 -
Sales 2022 585 M - -
Net income 2022 -38,9 M - -
Net Debt 2022 127 M - -
P/E ratio 2022 -274x
Yield 2022 -
Capitalization 9 628 M 9 628 M -
EV / Sales 2021 18,4x
EV / Sales 2022 16,7x
Nbr of Employees 1 023
Free-Float 86,7%
More Financials
Company
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through... 
More about the company
Ratings of NovoCure Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVOCURE LIMITED
12/07NOVOCURE : Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New H..
PU
12/07Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New ..
BU
12/07NOVOCURE LTD : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
AQ
12/06Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research P..
BU
11/29INSIDER BUY : NovoCure
MT
11/23Novocure to Participate in Two Upcoming Investor Conferences
BU
11/22NovoCure Completes Patient Enrollment in Phase 3 Trial of Tumor Treating Fields in Non..
MT
11/22Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treati..
BU
11/22NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumo..
CI
11/15Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncol..
BU
11/152-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblasto..
BU
11/15Novocure Announces 2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly D..
CI
10/28Wedbush Adjusts Price Target for NovoCure to $85 From $101, Maintains Underperform Rati..
MT
10/28NOVOCURE : Q3 Earnings Snapshot
AQ
10/28NovoCure Swings to Net Loss in Q3 Despite Higher Revenue
MT
More news
News in other languages on NOVOCURE LIMITED
11/22NovoCure complète le recrutement des patients dans l'essai de phase 3 des champs de tra..
10/28NovoCure subit une perte nette au troisième trimestre malgré une hausse des revenus
10/28Earnings Flash (NVCR) NOVOCURE affiche un chiffre d'affaires de 133,6 millions de dolla..
10/04Zai Lab et Novocure lancent un essai de phase 2 sur la bithérapie contre le cancer gast..
09/28NOVOCURE : a signé un accord avec Roche
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Stock Trading Strategies
NOVOCURE LIMITED - 01/28
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | NVCR | JE00BYSS4X48 | MarketScreener
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Last Close Price 92,74 $
Average target price 119,33 $
Spread / Average Target 28,7%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-46.41%9 628
MASIMO CORPORATION6.74%15 819
GETINGE AB103.44%11 766
PENUMBRA, INC.49.47%9 772
SHOCKWAVE MEDICAL, INC.87.52%6 867
IRAY TECHNOLOGY COMPANY LIMITED218.50%6 253